MET and non-small cell lung carcinoma: As seen in EGRF mutant NSCLC, off-target mechanisms such as MET amplification confer resistance to tyrosine kinase inhibitors (TKIs) by activating the HGF/MET pathway that leads to AKT and ERK activation bypassing RAS (47).